Bone Modifiers - Tymlos
Customize your policy alerts
Sign up for Cigna Policy IP0329 alerts
Get alerted when Policy IP0329 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity coverage for Tymlos subcutaneous injection for osteoporosis treatment in postmenopausal patients and men. Coverage is subject to the member's benefit plan, applicable law, and the clinical criteria in this policy.
Bonsity was added to the preferred product criteria for Tymlos.
A postmenopausal osteoporosis exception was added allowing the bisphosphonate trial requirement to be bypassed when the patient has a very low T-score below -3.0.
The policy title was changed from Abaloparatide to Bone Modifiers - Tymlos.
The concurrent-use exclusion was clarified to state that calcium and vitamin D supplements may be used with Tymlos.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.